GNL1

Summary

GNL1 (G protein nucleolar 1, HGNC:4413) is a protein-coding gene on chromosome 6p21.33, encoding Guanine nucleotide-binding protein-like 1 (P36915). Possible regulatory or functional link with the histocompatibility cluster.

The GNL1 gene, identified in the human major histocompatibility complex class I region, shows a high degree of similarity with its mouse counterpart. The GNL1 gene is located less than 2 kb centromeric to HLA-E, in the same transcriptional orientation. GNL1 is telomeric to HLA-B and HLA-C.

Source: NCBI Gene 2794 — RefSeq curated summary.

At a glance

• GWAS associations: 22
• Clinical variants (ClinVar): 78 total
• MANE Select transcript: NM_005275

Identifiers

Gene identifiers

Field	Value
HGNC ID	HGNC:4413
Approved symbol	GNL1
Name	G protein nucleolar 1
Location	6p21.33
Locus type	gene with protein product
Status	Approved
Aliases	HSR1
Ensembl gene	ENSG00000204590
Ensembl biotype	protein_coding
OMIM	143024
Entrez	2794

Gene structure

Transcript identifiers

Ensembl transcripts: 13 — 10 protein_coding, 3 retained_intron

ENST00000376621, ENST00000433809, ENST00000462708, ENST00000464231, ENST00000487166, ENST00000863388, ENST00000911424, ENST00000911425, ENST00000911426, ENST00000911427, ENST00000911428, ENST00000911429, ENST00000958484

RefSeq mRNA: 1 — MANE Select: NM_005275 NM_005275

CCDS: CCDS4680

Canonical transcript exons

ENST00000376621 — 12 exons

Exon	Start	End
ENSE00001644497	30552467	30552661
ENSE00001648269	30546696	30546836
ENSE00001657109	30555555	30555720
ENSE00001664395	30555055	30555191
ENSE00001670423	30554764	30554915
ENSE00001680442	30553084	30553179
ENSE00001769073	30554575	30554646
ENSE00001932362	30541381	30546313
ENSE00001952253	30556131	30556489
ENSE00002206761	30553350	30553557
ENSE00003518954	30547352	30547530
ENSE00003616476	30547112	30547274

Expression profiles

Bgee: expression breadth ubiquitous, 134 present calls, max score 97.36.

FANTOM5 (CAGE): breadth ubiquitous, TPM avg 30.0773 / max 177.2784, expressed in 1820 samples.

FANTOM5 promoters (8 alternative TSS)

Promoter ID	TPM avg	Samples expressed
72531	7.2424	1763
72533	6.3806	1722
72530	5.7905	1684
72536	3.9924	1420
72534	3.1232	1420
72532	2.9651	1370
72529	0.5167	280
72535	0.0665	19

Top tissues by expression

134 total, by Bgee expression score (0-100, higher = more expressed):

Tissue	Anatomy ID	Expression score	Quality
right testis	UBERON:0004534	97.36	gold quality
left testis	UBERON:0004533	97.34	gold quality
stromal cell of endometrium	CL:0002255	97.21	gold quality
left ovary	UBERON:0002119	96.88	gold quality
ovary	UBERON:0000992	96.77	gold quality
endocervix	UBERON:0000458	96.59	gold quality
right ovary	UBERON:0002118	96.59	gold quality
testis	UBERON:0000473	96.12	gold quality
left uterine tube	UBERON:0001303	96.06	gold quality
body of uterus	UBERON:0009853	95.96	gold quality
left lobe of thyroid gland	UBERON:0001120	95.95	gold quality
thyroid gland	UBERON:0002046	95.95	gold quality
right lobe of thyroid gland	UBERON:0001119	95.91	gold quality
ectocervix	UBERON:0012249	95.89	gold quality
adenohypophysis	UBERON:0002196	95.79	gold quality
body of pancreas	UBERON:0001150	95.74	gold quality
pituitary gland	UBERON:0000007	95.72	gold quality
uterine cervix	UBERON:0000002	95.55	gold quality
myometrium	UBERON:0001296	95.47	gold quality
gall bladder	UBERON:0002110	95.28	gold quality
upper lobe of left lung	UBERON:0008952	95.24	gold quality
mucosa of stomach	UBERON:0001199	95.20	gold quality
placenta	UBERON:0001987	95.19	gold quality
right lung	UBERON:0002167	95.17	gold quality
pancreas	UBERON:0001264	95.05	gold quality
fallopian tube	UBERON:0003889	95.05	gold quality
right uterine tube	UBERON:0001302	94.83	gold quality
descending thoracic aorta	UBERON:0002345	94.82	gold quality
prostate gland	UBERON:0002367	94.79	gold quality
vagina	UBERON:0000996	94.78	gold quality

Single-cell (SCXA)

Detected in 2 experiment(s), a significant marker in 1.

Experiment	Marker?	Max mean expression
E-ANND-3	yes	5.17
E-GEOD-75367	no	40.00

Regulation

Is transcription factor: no

Upstream regulators (CollecTRI, top): AR

miRNA regulators (miRDB)

127 targeting GNL1, top 30 by miRDB confidence (max_score; target_count = how many genes the miRNA targets in total — lower means more specific):

miRNA	Max score	Avg score	miRNA target_count
HSA-MIR-126-5P	100.00	72.71	3180
HSA-MIR-6833-3P	100.00	70.63	3197
HSA-MIR-4768-5P	100.00	69.49	2861
HSA-MIR-4795-3P	100.00	74.62	4024
HSA-MIR-6873-3P	100.00	71.42	2626
HSA-MIR-4481	100.00	66.42	1669
HSA-MIR-513B-5P	99.99	69.96	2150
HSA-MIR-548C-3P	99.99	74.01	7587
HSA-MIR-3667-3P	99.99	67.17	1636
HSA-MIR-8068	99.98	73.85	2376
HSA-MIR-1229-3P	99.97	66.49	906
HSA-MIR-141-3P	99.94	72.79	2421
HSA-MIR-200A-3P	99.94	72.68	2420
HSA-MIR-6845-3P	99.94	66.88	1439
HSA-MIR-515-5P	99.92	69.82	2343
HSA-MIR-519E-5P	99.92	69.62	2358
HSA-MIR-652-5P	99.91	67.49	505
HSA-MIR-1297	99.91	73.41	3162
HSA-MIR-4753-3P	99.90	71.03	3786
HSA-MIR-95-5P	99.89	72.17	3973
HSA-MIR-629-3P	99.85	67.99	1875
HSA-MIR-4728-5P	99.85	69.39	4718
HSA-MIR-6515-3P	99.82	68.19	1933
HSA-MIR-6785-5P	99.82	68.68	4428
HSA-MIR-489-3P	99.80	66.46	839
HSA-MIR-4694-3P	99.79	69.53	2640
HSA-MIR-4713-5P	99.78	67.80	1794
HSA-MIR-623	99.76	68.16	1170
HSA-MIR-2116-3P	99.74	64.32	889
HSA-MIR-149-3P	99.72	68.22	3963

Literature-anchored findings (GeneRIF, showing 4)

• The results demonstrated that multiple mechanisms are involved in the translocation of GNL1 to the nucleolus in a cell cycle-dependent manner to regulate cell growth and proliferation. (PMID:22244851)
• The results suggested that SNPs at PRR3 and ABCF1 genes and the haplotype composed by SNPs at GNL1 and PRR3 between the HLA-A and HLA-C genes tended to predict Graves ophthalmology in a gender-dependent manner in patients with Graves Disease in Taiwan. (PMID:24908204)
• cross-talk between GNL1 and RPS20 is critical to promote cell proliferation. (PMID:30061673)
• Guanine nucleotide binding protein like-1 (GNL1) promotes cancer cell proliferation and survival through AKT/p21 (CIP1) signaling cascade. (PMID:33147101)

Cross-species orthologs

4 orthologs

Organism	Symbol	Gene ID
danio_rerio	gnl1	ENSDARG00000061789
mus_musculus	Gnl1	ENSMUSG00000024429
rattus_norvegicus	Gnl1	ENSRNOG00000000798
drosophila_melanogaster	Ns4	FBGN0032882

Paralogs (6): LSG1 (ENSG00000041802), NOA1 (ENSG00000084092), GNL3L (ENSG00000130119), GNL2 (ENSG00000134697), MTG1 (ENSG00000148824), GNL3 (ENSG00000163938)

Protein

Protein identifiers

Guanine nucleotide-binding protein-like 1 — P36915 (reviewed: P36915)

Alternative names: GTP-binding protein HSR1

All UniProt accessions (3): A0A024RCR2, A2AB27, P36915

UniProt curated annotations — full annotation on UniProt →

Function. Possible regulatory or functional link with the histocompatibility cluster.

Domain organisation. In contrast to other GTP-binding proteins, this family is characterized by a circular permutation of the GTPase motifs described by a G4-G1-G3 pattern.

Similarity. Belongs to the TRAFAC class YlqF/YawG GTPase family.

Isoforms (2)

UniProt ID	Names	Canonical?
P36915-1	1	yes
P36915-2	2

RefSeq proteins (1): NP_005266* (*=MANE)

Domains & families (InterPro)

ID	Name	Type
IPR006073	GTP-bd	Domain
IPR027417	P-loop_NTPase	Homologous_superfamily
IPR030378	G_CP_dom	Domain
IPR043358	GNL1-like	Family

Pfam: PF01926

UniProt features (27 total): modified residue 11, sequence conflict 4, compositionally biased region 3, binding site 3, region of interest 2, splice variant 2, chain 1, domain 1

Structure

Experimental structures (PDB)

0 structures.

Predicted structure (AlphaFold)

Model	pLDDT	Fraction very-high
AF-P36915-F1	77.41	0.53

Functional residue map

Curated UniProt residues grouped by drug-discovery relevance — catalytic, ligand-binding, modification, and mutation-validated positions. Source: UniProtKB sequence features.

Ligand- & substrate-binding residues (3): 225–228; 367–374; 411–415

Post-translational modifications (11): 32, 33, 34, 48, 50, 51, 68, 324, 561, 562, 563

Function

Pathways and Gene Ontology

Reactome pathways

0 pathways

MSigDB gene sets: 153 (showing top): ATF_B, CMYB_01, TTTGTAG_MIR520D, GRAESSMANN_APOPTOSIS_BY_DOXORUBICIN_DN, GRAESSMANN_RESPONSE_TO_MC_AND_DOXORUBICIN_DN, DACOSTA_UV_RESPONSE_VIA_ERCC3_UP, CREBP1_Q2, GOBP_LEUKOCYTE_MEDIATED_IMMUNITY, CREB_Q4, GOBP_LYMPHOCYTE_MEDIATED_IMMUNITY, E4F1_Q6, GOBP_DNA_DAMAGE_RESPONSE, GOBP_ADAPTIVE_IMMUNE_RESPONSE, ATF3_Q6, CREB_Q2_01

GO Biological Process (3): T cell mediated immunity (GO:0002456), DNA damage response (GO:0006974), signal transduction (GO:0007165)

GO Molecular Function (4): GTPase activity (GO:0003924), structural molecule activity (GO:0005198), GTP binding (GO:0005525), nucleotide binding (GO:0000166)

GO Cellular Component (2): obsolete extracellular space (GO:0005615), nucleus (GO:0005634)

GO top-level categories

Rollup of top GO terms by namespace:

Category	Terms
lymphocyte mediated immunity	1
adaptive immune response based on somatic recombination of immune receptors built from immunoglobulin superfamily domains	1
cellular response to stress	1
cell communication	1
cellular process	1
signaling	1
regulation of cellular process	1
cellular response to stimulus	1
ribonucleoside triphosphate phosphatase activity	1
molecular_function	1
guanyl ribonucleotide binding	1
purine ribonucleoside triphosphate binding	1
nucleoside phosphate binding	1
heterocyclic compound binding	1
intracellular membrane-bounded organelle	1

Protein interactions and networks

STRING

2485 interactions, top by confidence (×1000):

Protein A	Protein B	Partner UniProt	Score
GNL1	EEF1A1	P04719	970
GNL1	HSF1	Q00613	839
GNL1	EEF1A2	P54266	713
GNL1	HLA-E	P13747	620
GNL1	MITD1	Q8WV92	540
GNL1	PPP1R11	O60927	532
GNL1	BOP1	Q14137	532
GNL1	C6orf136	Q5SQH8	519
GNL1	TCF19	Q9Y242	508
GNL1	GTPBP4	Q9BZE4	481
GNL1	ABCF1	Q8NE71	476
GNL1	SMCHD1	A6NHR9	469
GNL1	HLA-C	P04222	464
GNL1	XPO1	O14980	455
GNL1	PRKN	O60260	454

IntAct

54 interactions, top by confidence:

A	B	Type	Score
CFTR	ESYT2	psi-mi:“MI:2364”(proximity)	0.710
DYNC1I2	DYNC1LI2	psi-mi:“MI:0914”(association)	0.680
SLC2A12	METTL15	psi-mi:“MI:0914”(association)	0.530
KLHL40	CBX4	psi-mi:“MI:0914”(association)	0.530
WDCP	PAPSS1	psi-mi:“MI:0914”(association)	0.530
ABCF2	AHCYL1	psi-mi:“MI:0914”(association)	0.530
GNL1	CSNK2A2	psi-mi:“MI:0914”(association)	0.530
GNL1	FAU	psi-mi:“MI:0915”(physical association)	0.400
GNL1	HINT1	psi-mi:“MI:0915”(physical association)	0.400
FGB	NME2	psi-mi:“MI:0914”(association)	0.350
TULP3	PPP1R12A	psi-mi:“MI:0914”(association)	0.350
DYNC1I2	DYNC1LI2	psi-mi:“MI:0914”(association)	0.350
CCDC116	PAPSS1	psi-mi:“MI:0914”(association)	0.350
PAPSS1	PAPSS2	psi-mi:“MI:0914”(association)	0.350
CSNK2A1	RPS3A	psi-mi:“MI:0914”(association)	0.350
CSNK2A2	VWA8	psi-mi:“MI:0914”(association)	0.350
CSNK2B	OSBPL8	psi-mi:“MI:0914”(association)	0.350
PGK1	PRPF6	psi-mi:“MI:0914”(association)	0.350
RACK1	RPS3A	psi-mi:“MI:0914”(association)	0.350
RPL19	RPS3A	psi-mi:“MI:0914”(association)	0.350
RPL4	EIF3CL	psi-mi:“MI:0914”(association)	0.350
SRP14	EIF3F	psi-mi:“MI:0914”(association)	0.350
FGB	KIF2A	psi-mi:“MI:0914”(association)	0.350
PAPSS1	ASMTL	psi-mi:“MI:0914”(association)	0.350

BioGRID (114): GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Co-fractionation), GNL1 (Affinity Capture-MS)

ESM2 similar proteins: A2VD13, A4D126, A5PK43, A6H751, A7E3N7, B0S6U7, B0S8I0, B5DFG1, D2GU20, E1BCH6, O75127, O75616, O95382, P36915, P36916, P48760, Q05932, Q2TBP8, Q2VPK5, Q3SZK4, Q3U269, Q3U5Q7, Q3V300, Q4R8D2, Q5E9Z1, Q5EBA0, Q5ND52, Q5QJC3, Q5R655, Q5RA07, Q5RJG7, Q5S6T3, Q5TM59, Q6MG06, Q7YR35, Q8C2E4, Q8CJ00, Q8JIF5, Q8K045, Q8NC60

Diamond homologs: A2XGQ1, A4SDB8, A5GR60, A5IMB8, A5N2K5, A5VWQ6, A6LT31, A8EXG4, A8GM60, A8GQS1, A8GUK6, A9KFU3, A9NDV6, B0JFL6, B0KG04, B1JFJ3, B1LBK5, B1X0B0, B2TPB6, B2UX10, B3EGV8, B3PN57, B3QQY9, B3WE42, B4S596, B6J7Q3, B7K1S0, B8GAY7, B8I8N7, B9K8C0, C3PMD9, C4K1B9, J9VQ03, O14236, O67679, O74791, P0CS94, P36915, P36916, P40010

SIGNOR signaling

0 interactions.

Enriched among interaction partners

Reactome pathways and GO biological processes over-represented among this gene’s 63 IntAct physical interaction partners (hypergeometric vs the genome-wide background, BH-FDR, gene-set size 15–500, ranked by fold). A functional readout of the neighbourhood — distinct from this gene’s own memberships above, and biased toward well-studied / hub proteins, so read it as themes rather than proof.

Reactome pathways:

Pathway	Partners	Fold	FDR
Formation of a pool of free 40S subunits	5	11.4×	2e-03
L13a-mediated translational silencing of Ceruloplasmin expression	5	10.3×	2e-03
SRP-dependent cotranslational protein targeting to membrane	5	10.2×	2e-03
GTP hydrolysis and joining of the 60S ribosomal subunit	5	10.2×	2e-03
mRNA Splicing - Major Pathway	6	6.7×	4e-03
Translation	5	6.3×	9e-03

GO biological processes:

GO term	Partners	Fold	FDR
negative regulation of proteasomal ubiquitin-dependent protein catabolic process	5	34.0×	1e-04
cytoplasmic translation	6	18.8×	1e-04

Disease & clinical

Clinical variants and AI predictions

ClinVar

78 variants total. Per-class counts are floors (≥ shown; pagination cap):

Classification	Count (floor)
Pathogenic	0
Likely pathogenic	0
Uncertain significance	57
Likely benign	2
Benign	0

Top pathogenic / likely-pathogenic (0)

SpliceAI

1809 predictions. Top by Δscore:

Variant	Effect	Δscore
6:30546692:TGACC:T	donor_loss	1.0000
6:30546695:CCTTT:C	donor_gain	1.0000
6:30546711:AG:A	donor_gain	1.0000
6:30546832:CCAGG:C	acceptor_gain	1.0000
6:30546833:CAGG:C	acceptor_gain	1.0000
6:30546833:CAGGC:C	acceptor_gain	1.0000
6:30546834:AGG:A	acceptor_gain	1.0000
6:30546835:GG:G	acceptor_gain	1.0000
6:30546837:C:CC	acceptor_gain	1.0000
6:30547108:TCAC:T	donor_loss	1.0000
6:30547111:C:CA	donor_loss	1.0000
6:30547271:GAAC:G	acceptor_gain	1.0000
6:30547272:AAC:A	acceptor_gain	1.0000
6:30547273:AC:A	acceptor_gain	1.0000
6:30547274:CC:C	acceptor_gain	1.0000
6:30547275:C:CC	acceptor_gain	1.0000
6:30552662:C:CC	acceptor_gain	1.0000
6:30553180:C:CC	acceptor_gain	1.0000
6:30553187:C:CT	acceptor_gain	1.0000
6:30553188:A:T	acceptor_gain	1.0000
6:30553349:CCA:C	donor_gain	1.0000
6:30553443:T:TA	donor_gain	1.0000
6:30554566:AGTAC:A	donor_loss	1.0000
6:30554567:GTACT:G	donor_loss	1.0000
6:30554568:TAC:T	donor_loss	1.0000
6:30554569:ACT:A	donor_loss	1.0000
6:30554570:CTC:C	donor_loss	1.0000
6:30554571:TC:T	donor_loss	1.0000
6:30554572:CA:C	donor_loss	1.0000
6:30554573:A:AC	donor_gain	1.0000

AlphaMissense

3920 scored. Top likely-pathogenic:

Variant	Protein change	am_pathogenicity
6:30547116:A:C	C479W	1.000
6:30547117:C:T	C479Y	1.000
6:30554631:A:G	W182R	1.000
6:30554631:A:T	W182R	1.000
6:30554643:A:G	W178R	1.000
6:30554643:A:T	W178R	1.000
6:30546773:G:T	A502D	0.999
6:30546776:G:T	A501E	0.999
6:30546778:T:A	R500S	0.999
6:30546778:T:G	R500S	0.999
6:30546779:C:A	R500I	0.999
6:30546779:C:G	R500T	0.999
6:30546789:C:G	D497H	0.999
6:30546831:C:G	A483P	0.999
6:30547118:A:G	C479R	0.999
6:30547390:C:G	G414R	0.999
6:30547394:G:C	C412W	0.999
6:30547397:G:C	D411E	0.999
6:30547397:G:T	D411E	0.999
6:30547398:T:A	D411V	0.999
6:30547398:T:C	D411G	0.999
6:30547398:T:G	D411A	0.999
6:30547452:C:T	G393D	0.999
6:30547453:C:G	G393R	0.999
6:30547512:T:A	K373M	0.999
6:30547515:C:T	G372E	0.999
6:30553446:A:G	W238R	0.999
6:30553446:A:T	W238R	0.999
6:30553480:C:A	K226N	0.999
6:30553480:C:G	K226N	0.999

dbSNP variants (sampled 300 via entrez): RS1001394831 (6:30558297 A>G), RS1001406535 (6:30551937 A>T), RS1001418217 (6:30544101 G>A), RS1001476892 (6:30543792 C>T), RS1002401263 (6:30544412 C>A,G,T), RS1002778126 (6:30544135 T>C), RS1002809569 (6:30554593 G>A), RS1003065219 (6:30548130 T>C), RS1003388554 (6:30553317 C>A,T), RS1003475422 (6:30557932 A>G), RS1003755192 (6:30549881 T>C,G), RS1003764487 (6:30542553 G>T), RS1003809864 (6:30546441 A>T), RS1003818499 (6:30542122 C>G,T), RS1003872791 (6:30545417 C>T)

Disease associations

OMIM: gene MIM:143024 | disease phenotypes:

GenCC curated gene-disease

Mondo (0):

Orphanet (0):

HPO phenotypes

0 total (0 of 0 shown, HPO-id order):

GWAS associations

22 associations (top):

Study	Trait	p-value
GCST004521_114	Autism spectrum disorder or schizophrenia	3.000000e-17
GCST004521_117	Autism spectrum disorder or schizophrenia	3.000000e-15
GCST004521_121	Autism spectrum disorder or schizophrenia	3.000000e-13
GCST004521_132	Autism spectrum disorder or schizophrenia	2.000000e-09
GCST004521_171	Autism spectrum disorder or schizophrenia	4.000000e-14
GCST004521_2	Autism spectrum disorder or schizophrenia	2.000000e-16
GCST004521_209	Autism spectrum disorder or schizophrenia	5.000000e-16
GCST004521_210	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_211	Autism spectrum disorder or schizophrenia	5.000000e-15
GCST004521_263	Autism spectrum disorder or schizophrenia	7.000000e-17
GCST004521_265	Autism spectrum disorder or schizophrenia	7.000000e-14
GCST004521_269	Autism spectrum disorder or schizophrenia	7.000000e-11
GCST004521_295	Autism spectrum disorder or schizophrenia	6.000000e-18
GCST004521_3	Autism spectrum disorder or schizophrenia	2.000000e-15
GCST004521_56	Autism spectrum disorder or schizophrenia	1.000000e-22
GCST004521_70	Autism spectrum disorder or schizophrenia	8.000000e-20
GCST004521_79	Autism spectrum disorder or schizophrenia	1.000000e-16
GCST004748_102	Lung cancer	2.000000e-18
GCST004750_52	Squamous cell lung carcinoma	5.000000e-14
GCST005232_23	Neuroticism	8.000000e-09
GCST005790_55	Rosacea symptom severity	2.000000e-06
GCST006041_32	Major depressive disorder	1.000000e-06

EFO canonical traits (2, from GWAS)

EFO ID	Trait name
EFO:0007660	neuroticism measurement
EFO:0009180	rosacea severity measurement

Drugs & pharmacology

Drug and pharmacology data

Is drug target: no

PharmGKB: 1 entry (VIP=true, CPIC=false)

CTD chemical–gene interactions

34 total (human), top 30 by PubMed support.

Chemical	Actions (top 5)	PubMed papers
Valproic Acid	affects expression, increases expression	3
Benzo(a)pyrene	affects methylation, decreases expression	2
aristolochic acid I	increases expression	1
FR900359	affects phosphorylation	1
bisphenol F	increases methylation	1
bisphenol A	affects cotreatment, increases methylation, decreases methylation	1
decabromobiphenyl ether	decreases expression	1
tris(1,3-dichloro-2-propyl)phosphate	decreases expression	1
sodium arsenite	increases expression	1
tetrabromobisphenol A	decreases expression	1
zinc chromate	decreases expression, increases abundance	1
coumarin	decreases phosphorylation	1
di-n-butylphosphoric acid	affects expression	1
chromium hexavalent ion	increases abundance, decreases expression	1
4-(5-benzo(1,3)dioxol-5-yl-4-pyridin-2-yl-1H-imidazol-2-yl)benzamide	increases expression, affects cotreatment	1
pentabrominated diphenyl ether 100	decreases expression	1
hexabrominated diphenyl ether 153	decreases expression	1
LDN 193189	affects cotreatment, increases expression	1
Sunitinib	increases expression	1
Fulvestrant	affects cotreatment, increases methylation	1
Air Pollutants	affects expression, increases abundance	1
Arsenic	affects methylation	1
Caffeine	decreases phosphorylation	1
Doxorubicin	decreases expression	1
Ozone	affects expression, increases abundance	1
Phthalic Acids	increases methylation	1
Quercetin	increases phosphorylation	1
Ribonucleotides	affects binding	1
Selenium	increases expression	1
Smoke	decreases expression	1

Clinical trials (associated diseases)

0 trials via MONDO — disease-level, not drug-specific.